Sitohang IBS, Anwar AI, Jusuf NK, Arimuko A, Norawati L, Veronica S
Trulicity (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes
Despite Wegovy and Zepbound being approved for patients with a body mass index of 30 or greater, and 27 or greater for those with at least one weight-related ailment, some insurance plans require a higher BMI or additional criteria for coverageif they cover medications for obesity at all
While not yet approved for addiction treatment, GLP-1RAs hold significant potential in addressing addictions complex neurobiological underpinnings
In the United States, semaglutide isnt available as a generic drug
Semaglutide thereby enhances serotonin release or receptor sensitivity